Ravi Uppaluri, MDPhD
@DrUppaluri
Followers
1K
Following
1K
Media
48
Statuses
319
Director, Head and Neck Surgical Oncology, Chief of Otolaryngology, Brigham and Women’s and Dana-Farber Cancer Institute
Boston, MA
Joined March 2016
RT @ASCOPost: Interim results from KEYNOTE-689 (NEJM): Perioperative pembrolizumab + standard care improved 3-yr EFS in locally advanced HN….
0
1
0
RT @sitcancer: Tomorrow is the #SITC Summit on the Future of Neoadjuvant Clinical Trial Design, which will discuss the recent advances in c….
0
16
0
Here it is! KEYNOTE-689 primary publication online now @NEJM. It’s been an incredible journey with DAdkins @SitemanCenter @WUSM. All started in early 2010s / now with @US_FDA approval and a new standard of care! @DanaFarberNews @BrighamWomens @BrighamSurgery.
4
30
82
RT @PiccirilloJay: Exciting news in the head and neck cancer space. KEYNOTE-689 resulted in the first FDA approval for patients with HNSCC….
fda.gov
On June 12, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for adults with resectable locally advanced head and neck squamous c
0
5
0
RT @AACR: The results of the KEYNOTE-689 trial that served as the basis for this approval were recently presented by @DrUppaluri of @Harvar….
aacr.org
Adding pembrolizumab before and after surgery to standard of care improved outcomes in previously untreated head and neck cancer patients.
0
4
0
RT @DanaFarberNews: #BREAKING The @FDA has approved pembrolizumab as the first new standard-of-care treatment for patients with resectable….
0
14
0
Thanks @DrGopalIyer !!! Has been quite a journey from an idea we had in the early 2010s to change standard of care (with DAdkins at WashU as a partner on all this work)- exciting news for our patients.
@DrUppaluri Not everyday someone gets to change practice. this is why we all do what we do….this is the dream!!!!.
0
0
10
RT @DrNeilGross: The standard of care has finally changed for patients with resectable head and neck #cancer!! Congratulations @DrUppaluri….
fda.gov
On June 12, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for adults with resectable locally advanced head and neck squamous c
0
13
0
RT @rbryanbell: Boom!💥 @FDA approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell c….
fda.gov
On June 12, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for adults with resectable locally advanced head and neck squamous c
0
21
0
RT @rbryanbell: If you are attending @AHNSinfo, please join Dr. Stephen Lai & me this evening (Wed) in Celestin E at 6:15pm for updates on….
0
2
0
RT @HemOncToday: “It’s really exciting. It’s a new frontier for our patients.” . @DrUppaluri of @DanaFarber discussed data from KEYNOTE-689….
healio.com
The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain patients with advanced head and neck squamous cell carcinoma, according to...
0
4
0
RT @DanaFarberNews: As #HeadAndNeckCancer Month comes to a close, we reflect on the exciting phase 3 clinical trial results shared by @Dana….
0
2
0
RT @DanaFarberNews: Adding perioperative pembrolizumab to standard of care is “a new frontier” for head and neck cancer, @DanaFarber's @DrU….
healio.com
The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain patients with advanced head and neck squamous cell carcinoma, according to...
0
4
0
RT @OncNewsCentral: #KEYNOTE689: Adding #Pembrolizumab before and after surgery significantly improves EFS in resectable LA-HNSCC. A potent….
oncologynewscentral.com
Adding perioperative pembrolizumab to standard of care significantly improves event-free survival in locally advanced head and neck squamous cell cancers.
0
5
0
RT @TargetedOnc: Keytruda Plus SOC: New Standard for Advanced Head & Neck Cancer | #AACR25 @DrUppaluri @DanaFarber.
targetedonc.com
Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head and neck cancer per KEYNOTE-689, introducing a potential new standard of...
0
1
0